Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation

Alan J. Bank, Sajad H. Mir, Duc Q. Nguyen, R. Morton Bolman, Sara J. Shumway, Leslie W. Miller, Daniel R. Kaiser, Sofia M. Ormaza, Soon J. Park

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Background. Left ventricular assist devices (LVADs) are increasingly being used to 'bridge' patients to heart transplantation. Methods. Data from 40 consecutive status 1 heart transplantation patients treated with intravenous inotrope therapy (n = 20) or the HeartMate LVAD (n = 20) were retrospectively analyzed. Results. Baseline clinical characteristics were similar in the two groups. At the time of transplantation, LVAD patients had significantly higher blood pressure and sodium with significantly lower blood urea nitrogen and creatinine. After transplantation, renal failure (52.6% versus 16.7%) and right heart failure (31.6% versus 5.6%) occurred more frequently (p < 0.05) in the inotrope group. Six-month survival after transplantation did not significantly differ in the inotrope or LVAD groups (73.7% versus 88.9%) but event-free survival was significantly (p < 0.05) lower in the inotrope group (15.8% versus 55.6%). Total hospital charges were significantly lower in the inotrope group ($213,860 ± $107,560 versus $342,620 ± $104,420), but average daily hospital charges were not different ($3,990 ± $1,300 versus $4,130 ± $2,050). Conclusions. Status 1 heart transplant patients treated with an LVAD as opposed to inotrope therapy have improved clinical and metabolic function at the time of transplant and improved survival to 6 months after transplant without major complications. Total costs are higher in the LVAD patients but average daily costs are similar. (C) 2000 by The Society of Thoracic Surgeons.

Original languageEnglish (US)
Pages (from-to)1369-1375
Number of pages7
JournalAnnals of Thoracic Surgery
Volume69
Issue number5
DOIs
StatePublished - May 2000
Externally publishedYes

Fingerprint

Heart-Assist Devices
Heart Transplantation
Hospital Charges
Transplantation
Transplants
Costs and Cost Analysis
Survival
Blood Urea Nitrogen
Disease-Free Survival
Renal Insufficiency
Creatinine
Heart Failure
Sodium
Hypertension
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Bank, A. J., Mir, S. H., Nguyen, D. Q., Bolman, R. M., Shumway, S. J., Miller, L. W., ... Park, S. J. (2000). Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation. Annals of Thoracic Surgery, 69(5), 1369-1375. https://doi.org/10.1016/S0003-4975(00)01083-3

Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation. / Bank, Alan J.; Mir, Sajad H.; Nguyen, Duc Q.; Bolman, R. Morton; Shumway, Sara J.; Miller, Leslie W.; Kaiser, Daniel R.; Ormaza, Sofia M.; Park, Soon J.

In: Annals of Thoracic Surgery, Vol. 69, No. 5, 05.2000, p. 1369-1375.

Research output: Contribution to journalArticle

Bank, AJ, Mir, SH, Nguyen, DQ, Bolman, RM, Shumway, SJ, Miller, LW, Kaiser, DR, Ormaza, SM & Park, SJ 2000, 'Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation', Annals of Thoracic Surgery, vol. 69, no. 5, pp. 1369-1375. https://doi.org/10.1016/S0003-4975(00)01083-3
Bank, Alan J. ; Mir, Sajad H. ; Nguyen, Duc Q. ; Bolman, R. Morton ; Shumway, Sara J. ; Miller, Leslie W. ; Kaiser, Daniel R. ; Ormaza, Sofia M. ; Park, Soon J. / Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation. In: Annals of Thoracic Surgery. 2000 ; Vol. 69, No. 5. pp. 1369-1375.
@article{782bf6b8fa904dbf9f4f2db85c54be81,
title = "Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation",
abstract = "Background. Left ventricular assist devices (LVADs) are increasingly being used to 'bridge' patients to heart transplantation. Methods. Data from 40 consecutive status 1 heart transplantation patients treated with intravenous inotrope therapy (n = 20) or the HeartMate LVAD (n = 20) were retrospectively analyzed. Results. Baseline clinical characteristics were similar in the two groups. At the time of transplantation, LVAD patients had significantly higher blood pressure and sodium with significantly lower blood urea nitrogen and creatinine. After transplantation, renal failure (52.6{\%} versus 16.7{\%}) and right heart failure (31.6{\%} versus 5.6{\%}) occurred more frequently (p < 0.05) in the inotrope group. Six-month survival after transplantation did not significantly differ in the inotrope or LVAD groups (73.7{\%} versus 88.9{\%}) but event-free survival was significantly (p < 0.05) lower in the inotrope group (15.8{\%} versus 55.6{\%}). Total hospital charges were significantly lower in the inotrope group ($213,860 ± $107,560 versus $342,620 ± $104,420), but average daily hospital charges were not different ($3,990 ± $1,300 versus $4,130 ± $2,050). Conclusions. Status 1 heart transplant patients treated with an LVAD as opposed to inotrope therapy have improved clinical and metabolic function at the time of transplant and improved survival to 6 months after transplant without major complications. Total costs are higher in the LVAD patients but average daily costs are similar. (C) 2000 by The Society of Thoracic Surgeons.",
author = "Bank, {Alan J.} and Mir, {Sajad H.} and Nguyen, {Duc Q.} and Bolman, {R. Morton} and Shumway, {Sara J.} and Miller, {Leslie W.} and Kaiser, {Daniel R.} and Ormaza, {Sofia M.} and Park, {Soon J.}",
year = "2000",
month = "5",
doi = "10.1016/S0003-4975(00)01083-3",
language = "English (US)",
volume = "69",
pages = "1369--1375",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation

AU - Bank, Alan J.

AU - Mir, Sajad H.

AU - Nguyen, Duc Q.

AU - Bolman, R. Morton

AU - Shumway, Sara J.

AU - Miller, Leslie W.

AU - Kaiser, Daniel R.

AU - Ormaza, Sofia M.

AU - Park, Soon J.

PY - 2000/5

Y1 - 2000/5

N2 - Background. Left ventricular assist devices (LVADs) are increasingly being used to 'bridge' patients to heart transplantation. Methods. Data from 40 consecutive status 1 heart transplantation patients treated with intravenous inotrope therapy (n = 20) or the HeartMate LVAD (n = 20) were retrospectively analyzed. Results. Baseline clinical characteristics were similar in the two groups. At the time of transplantation, LVAD patients had significantly higher blood pressure and sodium with significantly lower blood urea nitrogen and creatinine. After transplantation, renal failure (52.6% versus 16.7%) and right heart failure (31.6% versus 5.6%) occurred more frequently (p < 0.05) in the inotrope group. Six-month survival after transplantation did not significantly differ in the inotrope or LVAD groups (73.7% versus 88.9%) but event-free survival was significantly (p < 0.05) lower in the inotrope group (15.8% versus 55.6%). Total hospital charges were significantly lower in the inotrope group ($213,860 ± $107,560 versus $342,620 ± $104,420), but average daily hospital charges were not different ($3,990 ± $1,300 versus $4,130 ± $2,050). Conclusions. Status 1 heart transplant patients treated with an LVAD as opposed to inotrope therapy have improved clinical and metabolic function at the time of transplant and improved survival to 6 months after transplant without major complications. Total costs are higher in the LVAD patients but average daily costs are similar. (C) 2000 by The Society of Thoracic Surgeons.

AB - Background. Left ventricular assist devices (LVADs) are increasingly being used to 'bridge' patients to heart transplantation. Methods. Data from 40 consecutive status 1 heart transplantation patients treated with intravenous inotrope therapy (n = 20) or the HeartMate LVAD (n = 20) were retrospectively analyzed. Results. Baseline clinical characteristics were similar in the two groups. At the time of transplantation, LVAD patients had significantly higher blood pressure and sodium with significantly lower blood urea nitrogen and creatinine. After transplantation, renal failure (52.6% versus 16.7%) and right heart failure (31.6% versus 5.6%) occurred more frequently (p < 0.05) in the inotrope group. Six-month survival after transplantation did not significantly differ in the inotrope or LVAD groups (73.7% versus 88.9%) but event-free survival was significantly (p < 0.05) lower in the inotrope group (15.8% versus 55.6%). Total hospital charges were significantly lower in the inotrope group ($213,860 ± $107,560 versus $342,620 ± $104,420), but average daily hospital charges were not different ($3,990 ± $1,300 versus $4,130 ± $2,050). Conclusions. Status 1 heart transplant patients treated with an LVAD as opposed to inotrope therapy have improved clinical and metabolic function at the time of transplant and improved survival to 6 months after transplant without major complications. Total costs are higher in the LVAD patients but average daily costs are similar. (C) 2000 by The Society of Thoracic Surgeons.

UR - http://www.scopus.com/inward/record.url?scp=0033932905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033932905&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(00)01083-3

DO - 10.1016/S0003-4975(00)01083-3

M3 - Article

C2 - 10881807

AN - SCOPUS:0033932905

VL - 69

SP - 1369

EP - 1375

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 5

ER -